Status:
Concluded with an LOI
Manufacturer:
UCB Canada Inc.
Indication:
Epilepsy, partial-onset seizures
Last updated October 22, 2018
Status:
Concluded with an LOI
Manufacturer:
Raptor Pharmaceuticals Inc.
Indication:
Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections
Last updated October 11, 2018
Fibristal (ulipristal acetate)
Status:
Concluded without agreement
Manufacturer:
Allergan Inc.
Indication:
Uterine fibroids (signs and symptoms) - 2nd cycle pre-surgery
Last updated September 28, 2018
Status:
Concluded with an LOI
Manufacturer:
Biogen Canada Inc.
Indication:
Spinal Muscular Atrophy
Last updated September 26, 2018
Toujeo (insulin glargine injection)
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated September 12, 2018
Synjardy (empagliflozin/metformin)
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Diabetes Mellitus, Type 2
Last updated September 11, 2018
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Diabetes Mellitus, Type 2 with high cardiovascular risk
Last updated September 11, 2018
Dysport Therapeutic (abobotulinumtoxina)
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Lower Limb Spasticity
Last updated August 30, 2018
Status:
Concluded with an LOI
Manufacturer:
Amicus Therapeutics
Indication:
Fabry Disease
Last updated August 28, 2018
Enstilar (calcipotriol/betamethasone)
Status:
Concluded with an LOI
Manufacturer:
LEO Pharma Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated August 27, 2018